Corient Private Wealth LP Has $35.07 Million Holdings in Zoetis Inc. $ZTS

Corient Private Wealth LP lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 8.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 487,990 shares of the company's stock after selling 47,682 shares during the period. Corient Private Wealth LP owned 0.12% of Zoetis worth $35,067,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZTS. California State Teachers Retirement System raised its holdings in Zoetis by 6,680.3% during the 2nd quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company's stock worth $3,430,982,000 after purchasing an additional 47,041,186 shares during the last quarter. BlackRock Inc. raised its stake in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. J. Stern & Co. LLP raised its stake in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. State Street Corp lifted its holdings in Zoetis by 0.8% in the fourth quarter. State Street Corp now owns 19,796,891 shares of the company's stock valued at $2,490,845,000 after buying an additional 149,382 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company's stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. BNP Paribas Exane lowered their price target on Zoetis from $146.00 to $110.00 and set an "outperform" rating for the company in a research note on Tuesday, August 11th. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 1st. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, August 7th. Weiss Ratings reissued a "sell (d)" rating on shares of Zoetis in a report on Wednesday. Finally, UBS Group cut their price target on Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Zoetis presently has a consensus rating of "Hold" and a consensus target price of $101.08.

Zoetis Stock Performance

NYSE:ZTS opened at $73.05 on Monday. The firm has a market capitalization of $30.19 billion, a PE ratio of 12.03, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock's 50-day simple moving average is $75.56 and its 200 day simple moving average is $91.73. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $150.05.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company's quarterly revenue was down .2% on a year-over-year basis. During the same quarter last year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.